Background: Cervical cancer remains a major global public health concern, with an estimated 662,301 new cases and 348,874 deaths in 2022 (GLOBOCAN). Persistent infection with high-risk human papillomaviruses (HPV), particularly genotypes 16 and 18, accounts for approximately 70% of precancerous lesions. The genetic diversity of HPV influences disease progression, making genotyping essential for effective screening and prevention strategies. This study aimed to determine the prevalence and distribution of HPV genotypes among women attending the gynecology department of the Thies Regional Hospital Centre (CHRT), Senegal. Methods: A prospective, descriptive, and analytical study was conducted with 27 women consulting for cervical cancer screening or follow-up of precancerous lesions. Cervico-vaginal samples were analyzed using real-time PCR with the AllplexTM HPV28 Detection Kit (Seegene) on CFX96TM Bio-Rad. Sociodemographic and clinical data were collected via Google Forms, processed with Excel, and analyzed using RStudio 2025. Results: Among the 27 participants, only one tested positive for the HPV 53/82 complex, corresponding to a prevalence of 3.7%. The mean age was 44.8 years (range 30 - 64). Most participants were married, had never undergone prior HPV testing, and none had received HPV vaccination. Conclusion: The low levels of prior screening and the absence of HPV vaccination observed in this cohort reflect limited awareness and uptake of cervical cancer prevention measures. Although based on a small sample size, these preliminary findings suggest the need for further investigation into local prevention strategies. Further well-powered studies are needed to accurately characterize circulating HPV genotypes in THIES and to inform context-specific screening and vaccination programs.
References
[1]
eClinicalMedicine (2023) Global Strategy to Eliminate Cervical Cancer as a Public Health Problem: Are We on Track? eClinicalMedicine, 55, Article 101842. https://doi.org/10.1016/j.eclinm.2023.101842
[2]
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D.M., Piñeros, M., Znaor, A., etal. (2021) Cancer Statistics for the Year 2020: An Overview. InternationalJournalofCancer, 149, 778-789. https://doi.org/10.1002/ijc.33588
[3]
Wright, T.C.J. (2009) Natural History of HPV Infections. Journal of Family Practice, 58, S3-S7.
[4]
Gaete, S., Auguste, A., Bhakkan, B., Peruvien, J., Herrmann-Storck, C., Socrier, Y., etal. (2021) Frequent High-Risk HPV Co-Infections Excluding Types 16 or 18 in Cervical Neoplasia in Guadeloupe. BMCCancer, 21, Article No. 281. https://doi.org/10.1186/s12885-021-07940-3
[5]
Han, J., Zhang, L., Chen, Y., Zhang, Y., Wang, L., Cai, R., etal. (2025) Global HPV Vaccination Programs and Coverage Rates: A Systematic Review. eClinicalMedicine, 84, Article 103290. https://doi.org/10.1016/j.eclinm.2025.103290
[6]
Organisation Mondiale de la Santé (OMS) Stratégie mondiale en vue d’accélérer l’élimination du cancer du col de l’utérus en tant que problème de santé publique. https://www.who.int/fr/publications/i/item/9789240014107
[7]
Brisson, M., Kim, J.J., Canfell, K., Drolet, M., Gingras, G., Burger, E.A., etal. (2020) Impact of HPV Vaccination and Cervical Screening on Cervical Cancer Elimination: A Comparative Modelling Analysis in 78 Low-Income and Lower-Middle-Income Countries. TheLancet, 395, 575-590. https://doi.org/10.1016/s0140-6736(20)30068-4
[8]
Gupta, R., Gupta, S., Mehrotra, R. and Sodhani, P. (2017) Cervical Cancer Screening in Resource-Constrained Countries: Current Status and Future Directions. Asian Pacific Journal of Cancer Prevention, 18, 1461-1467.
[9]
Arbyn, M., Smith, S.B., Temin, S., Sultana, F. and Castle, P. (2018) Detecting Cervical Precancer and Reaching Underscreened Women by Using HPV Testing on Self Samples: Updated Meta-analyses. BMJ, 363, k4823. https://doi.org/10.1136/bmj.k4823
[10]
Wright, T.C., Stoler, M.H., Behrens, C.M., Sharma, A., Zhang, G. and Wright, T.L. (2015) Primary Cervical Cancer Screening with Human Papillomavirus: End of Study Results from the Athena Study Using HPV as the First-Line Screening Test. GynecologicOncology, 136, 189-197. https://doi.org/10.1016/j.ygyno.2014.11.076
[11]
Gage, J.C., Schiffman, M., Katki, H.A., Castle, P.E., Fetterman, B., Wentzensen, N., etal. (2014) Reassurance against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. JNCIJournaloftheNationalCancerInstitute, 106, dju153. https://doi.org/10.1093/jnci/dju153
[12]
Diop‐Ndiaye, H., Sastre‐Garau, X., Drame, A., Dembele, B., Ba, N.N., Diop‐Diongue, O., etal. (2021) Respective Prevalence of High‐Risk Hpvgenotypes in Cervical Neoplasia in Senegal. JournalofMedicalVirology, 93, 5110-5117. https://doi.org/10.1002/jmv.27020
[13]
Donkoh, E.T., Asmah, R.H., Agyemang-Yeboah, F., Dabo, E.O. and Wiredu, E.K. (2022) Prevalence and Distribution of Vaccine-Preventable Genital Human Papillomavirus (HPV) Genotypes in Ghanaian Women Presenting for Screening. CancerControl, 29, 1-11. https://doi.org/10.1177/10732748221094721
[14]
Porras, C., Bennett, C., Safaeian, M., Coseo, S., Rodríguez, A.C., González, P., etal. (2010) Determinants of Seropositivity among HPV-16/18 DNA Positive Young Women. BMCInfectiousDiseases, 10, Article No. 238. https://doi.org/10.1186/1471-2334-10-238
[15]
Ryser, M.D., Rositch, A. and Gravitt, P.E. (2017) Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual Revolution. TheJournalofInfectiousDiseases, 216, 604-611. https://doi.org/10.1093/infdis/jix333
[16]
Shi, R., Devarakonda, S., Liu, L., Taylor, H. and Mills, G. (2014) Factors Associated with Genital Human Papillomavirus Infection among Adult Females in the United States, NHANES 2007-2010. BMCResearchNotes, 7, Article No. 544. https://doi.org/10.1186/1756-0500-7-544
[17]
Kocjan, B.J., Seme, K., Močilnik, T., Jančar, N., Vrtačnik‐Bokal, E. and Poljak, M. (2007) Genomic Diversity of Human Papillomavirus Genotype 53 in an Ethnogeographically Closed Cohort of White European Women. JournalofMedicalVirology, 79, 431-438. https://doi.org/10.1002/jmv.20787
[18]
Schiffman, M. and de Sanjose, S. (2019) False Positive Cervical HPV Screening Test Results. PapillomavirusResearch, 7, 184-187. https://doi.org/10.1016/j.pvr.2019.04.012
[19]
IARC Working Group on the Evaluation of Cancer Preventive Interventions (2022) Cervical Cancer Screening. IARC Handbook of Cancer Prevention, Vol. 18, International Agency for Research on Cancer.
[20]
Zappacosta, R., Lattanzio, G., Viola, P., Ianieri, M.M., Gatta, D.M.P. and Rosini, S. (2014) A Very Rare Case of HPV-53-Related Cervical Cancer, in a 79-Year-Old Woman with a Previous History of Negative Pap Cytology. ClinicalInterventionsinAging, 9, 683-688. https://doi.org/10.2147/cia.s57294
[21]
Faye, B., Diallo, F., Sarr, H., Sembene, P.M. and Dieye, A. (2020) Molecular Genotyping of Human Papilloma Virus (HPV) in Women with Normal Endo-Cervical Cytology in Senegal. ScholarsAcademicJournalofBiosciences, 8, 23-29. https://doi.org/10.36347/sajb.2020.v08i02.002 https://saspublishers.com/media/articles/SAJB_82_23-29.pdf
[22]
Haute Autorité de Santé (2019) L’infection à HPV et l’histoire naturelle du cancer du col de l’utérus.
[23]
Division de la Lutte Contre les Maladies Non Transmissibles (2024) Normes et protocoles de dépistage des lésions précancéreuses du col de l’utérus et de détection précoce du cancer du sein. Ministère de la Santé. https://www.sante.gouv.sn/sites/default/files/NORMES%20ET%20PROTOCOLES%20DE%20DEPISTAGE%20DES%20LESIONS-min.pdf
